The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
 
Ying Cheng
No Relationships to Disclose
 
Ying Liu
No Relationships to Disclose
 
Jinhua Xu
No Relationships to Disclose
 
Jing Zhu
No Relationships to Disclose
 
Ying Wang
No Relationships to Disclose
 
Ying Xin
No Relationships to Disclose
 
Yanping Wang
No Relationships to Disclose
 
Chunjiao Wu
No Relationships to Disclose
 
Hongxia Cui
No Relationships to Disclose
 
Xianhong Liu
No Relationships to Disclose
 
Jixin Dai
No Relationships to Disclose
 
Zili Li
No Relationships to Disclose
 
XiangHua Zhang
No Relationships to Disclose
 
Jing Zhang
No Relationships to Disclose
 
Ben Zhang
No Relationships to Disclose